The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 683-690

  Geng, Fang ^a   Jiao, Zheng ^a   Dao, Yi Jun ^a   Qiu, Xiao Yan ^a   Ding, Jun Jie ^b   Shi, Xiao Jin ^a   Li, Zhong Dong ^a   Zhong, Ming Kang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

ABCC2; ABCG2; Mycophenolic acid; Pharmacokinetics; SLCO1B3; UGT1A8

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN; MYCOPHENOLIC ACID; PHENOLIC GLUCURONIDE; POLYPHENOL DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

ABCC2 GENE; ABCG2 GENE; ADULT; AGE; ALLELE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; GENE PROBE; GENE PRODUCT; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SLCO1B3 GENE; UGT1A8 GENE;

AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; DNA PRIMERS; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84862805282     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.12.003     Document Type: Article

References (52)

1. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
2. Rosso Felipe C., de Sandes T.V., Sampaio E.L., Park S.I., Silva H.T., Medina Pestana J.O. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009, 41:1441-1455.
3. Picard N., Yee S.W., Woillard J.B., et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010, 87:100-108.
4. Miura M., Kagaya H., Satoh S., et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008, 30:559-564.
5. Konig J., Seithel A., Gradhand U., Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:432-443.
6. Naesens M., Kuypers D.R., Verbeke K., Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006, 82:1074-1084.
7. Bullingham R.E., Nicholls A.J., Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34:429-455.
8. Jiao Z., Ding J.J., Shen J., et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol 2008, 65:893-907.
9. van Schaik R.H., van Agteren M., de Fijter J.W., et al. UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009, 86:319-327.
10. Schaub T.P., Kartenbeck J., Konig J., et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1997, 8:1213-1221.
11. Brunet M., Cirera I., Martorell J., et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006, 81:541-546.
12. Baldelli S., Merlini S., Perico N., et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007, 8:1127-1141.
13. Jirasiritham S., Sumethkul V., Mavichak V., Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 2004, 36:2076-2078.
14. de Jonge H., Kuypers D.R. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008, 22:6-20.
15. Sanchez-Fructuoso A.I., Maestro M.L., Calvo N., et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 2009, 41:2313-2316.
16. Bernard O., Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004, 32:775-778.
17. Levesque E., Delage R., Benoit-Biancamano M.O., et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007, 81:392-400.
18. Kuypers D.R., Naesens M., Vermeire S., Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005, 78:351-361.
19. Johnson L.A., Oetting W.S., Basu S., Prausa S., Matas A., Jacobson P.A. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol 2008, 64:1047-1056.
20. Saeki M., Saito Y., Jinno H., et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006, 6:63-75.
21. Innocenti F., Liu W., Chen P., Desai A.A., Das S., Ratain M.J. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005, 15:295-301.
22. Cheng Z., Radominska-Pandya A., Tephly T.R. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 1998, 356:301-305.
23. Bernard O., Tojcic J., Journault K., Perusse L., Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006, 34:1539-1545.
24. *3. Pharmacogenetics 2002, 12:287-297.
25. Seithel A., Glaeser H., Fromm M.F., Konig J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 2008, 4:51-64.
26. Yu X.Q., Xue C.C., Wang G., Zhou S.F. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr Drug Metab 2007, 8:787-802.
27. Itoda M., Saito Y., Shirao K., et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet 2003, 18:212-217.
28. Letschert K., Keppler D., Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004, 14:441-452.
29. Miura M., Satoh S., Inoue K., et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:1161-1169.
30. Albermann N., Schmitz-Winnenthal F.H., Z'Graggen K., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005, 70:949-958.
31. Masereeuw R., Notenboom S., Smeets P.H., Wouterse A.C., Russel F.G. Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. J Am Soc Nephrol 2003, 14:2741-2749.
32. Thervet E., Anglicheau D., Legendre C., Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008, 30:143-150.
33. Kuypers D.R., de Jonge H., Naesens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30:673-683.
34. Ishikawa T., Tsuji A., Inui K., et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 2004, 5:67-99.
35. Imai Y., Nakane M., Kage K., et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002, 1:611-616.
36. Zamber C.P., Lamba J.K., Yasuda K., et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13:19-28.
37. Zhang W., Yu B.N., He Y.J., et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006, 373:99-103.
38. Jiao Z., Zhong Y., Shen J., Yu Y.Q. Simple high-performance liquid chromatographic assay, with post-column derivatization, for simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. Chromatographia 2005, 62:363-371.
39. Kagaya H., Inoue K., Miura M., et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007, 63:279-288.
40. Zucker K., Rosen A., Tsaroucha A., et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997, 5:225-232.
41. Zhang W.X., Chen B., Jin Z., et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 2008, 38:1422-1436.
42. Yang J.W., Lee P.H., Hutchinson I.V., Pravica V., Shah T., Min D.I. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 2009, 31:542-548.
43. Zhao W., Fakhoury M., Deschenes G., et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010, 50:1280-1291.
44. Moriya Y., Nakamura T., Horinouchi M., et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002, 25:1356-1359.
45. Oswald S., Haenisch S., Fricke C., et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006, 79:206-217.
46. Meyer zu Schwabedissen H.E., Jedlitschky G., Gratz M., et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005, 33:896-904.
47. Nakahara T., Sakaeda T., Nakamura T., et al. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res 2004, 21:406-412.
48. Vogelgesang S., Kunert-Keil C., Cascorbi I., et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 2004, 23:223-231.
49. Cattaneo D., Perico N., Gaspari F., Gotti E., Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
50. Lam S., Partovi N., Ting L.S., Ensom M.H. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother 2008, 42:1037-1047.
51. Joy M.S., Boyette T., Hu Y., et al. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol 2010, 66:1119-1130.
52. Shipkova M., Armstrong V.W., Weber L., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002, 24:390-399.